| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-047 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司（以下简称"公司"）自成立以来，以"服 务亿万人群，走进千万家庭"为企业愿景，致力于为全球用户带来健康时尚的生 活方式，打造出系列智能按摩椅、按摩器等健康产品。 为了回馈股东朋友长期以来对公司的支持与厚爱，表达对投资者的感恩，同 时让广大股东深入了解体验公司的产品与服务，提高对公司业务与价值的理解与 认可，公司将举办"荣泰健康股东回馈特别活动"，本次活动具体方案如下： 一、活动时间 2025 年 7 月 28 日至 2025 年 8 月 18 日。若超过 2025 年 8 月 18 日 24:00 未 参与本次活动，则视为股东自动放弃参与本次活动的权利。 二、本次活动的股东范围 2025 年 7 月 28 日至 2025 年 8 月 18 日期间，在中国证券登记结算有限责任 公司上海分公司登记在册的公司全体股东。 三、活动内容 为了回馈股东朋友长期以来对公司的支持与厚爱，公司针对股东开展"荣泰 健 ...

内容概要：随着生活水平的提高，人们对健康养生的关注度显著增强，足底按摩器作为一种传统的养生 工具，有助于缓解疲劳、促进血液循环、改善睡眠质量，符合现代人对健康生活方式的追求。同时，我 国人口老龄化程度不断加深，老年人口占比逐渐攀升，为足底按摩器的发展提供庞大的用户基础。此 外，科技的快速发展为足底按摩器行业带来了新机遇。如物联网、大数据等技术的应用，让足底按摩器 的数据化、智能化趋势日益明显，产品功能不断升级，吸引了更多消费者。数据显示，2024年中国足底 按摩器行业市场规模达到4.46亿元，同比上涨6.01%。 相关上市企业：奥佳华（002614）、康泰智能（874525）、苏泊尔（002032）、倍轻松（688793）、荣 泰健康（603579）、京东集团-SW（09618）、阿里巴巴-W（09988）等。 相关企业：发美利健康器械(上海)有限公司、佛山市雅斯顿洁具有限公司、奥克斯集团有限公司、北京 卓雅信科技发展有限公司、上海泰昌健康科技股份有限公司、山东微步智能科技有限公司、上海江健电 气技术有限公司、浙江璐瑶电子科技有限公司、腾邦豪特（深圳）大健康产业有限公司、深圳市盟迪奥 科技股份有限公司等。 关 ...

Group 1 - Suzhou announced two new funds with a total scale of 100 billion RMB each, focusing on key areas such as biomedicine, AI, and integrated circuits [5] - Guangzhou plans to establish a 100 billion RMB digital industry fund, targeting software, semiconductors, and AI [5] - Foshan's new 10 billion RMB fund will focus on new energy and AI, aiming to enhance local industry competitiveness [6] Group 2 - Yangzhou's automotive and parts investment fund has been established with a scale of 12.5 billion RMB, focusing on innovative enterprises in the automotive sector [6] - Fourhui city government and Zhejiang Securities signed an agreement to establish a 10 billion RMB industry investment fund to attract key enterprises [7] - Inner Mongolia is selecting fund managers for its key industry guidance fund, requiring a minimum contribution of 2% from the manager [7] Group 3 - Jiangsu's new emerging industry mother fund has been established with a scale of 20 billion RMB, focusing on strategic emerging industries [9] - Jilin's automotive industry chain venture capital fund has been established with a total scale of 10 billion RMB, focusing on new energy vehicles [10] - Fujian's specialized fund has been registered with a target scale of 20 billion RMB, aimed at empowering specialized small and medium enterprises [11] Group 4 - The Shaanxi provincial innovation mother fund has been established with an initial scale of 100 billion RMB, focusing on technology innovation [12] - KKR announced the establishment of a 10 billion RMB smart energy fund, focusing on the renewable energy industry [14] - A new 10 billion RMB fund has been established in Nanjing, focusing on software and information technology sectors [14] Group 5 - The establishment of a 34.01 billion RMB health industry investment fund in Hubei aims to promote innovation in the health sector [18] - Renault and CICC signed an agreement to establish a new energy vehicle industry fund, focusing on battery and intelligent driving technologies [17] - The establishment of a 10 billion RMB fund by Cheng Tong Technology aims to invest in hard technology sectors [17]

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-046 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于公司参与股权投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的：嘉兴恩毅股权投资合伙企业（有限合伙）（以下简称"合伙 企业"、"本基金"或"嘉兴恩毅"） 投资金额：人民币 2,060 万元，持股比例占合伙企业本期募集认缴出资 总额的 99.52%。 风险提示： 1) 由于股权投资基金具有投资周期长、流动性低的特点，本次投资可能面 临较长的投资回收期； 2) 仅参与单一投资标的风险：基金拟投资上海傲鲨智能科技有限公司,存在 单一投资标的风险，包括不限于基金无法通过多种渠道、多种类标的等 方式分散投资风险，基金将面临单一项目的集中度风险。 3) 本基金投资标的的价值取决于投资对象的经营状况，原股东对所投资企 业的管理和运营，相关市场宏观调控政策、财政税收政策、产业政策、 法律 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-045 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 托理财投资受到市场波动的影响。公司将根据经济形势以及金融市场的变化 适时适量地介入，因此短期投资的实际收益不可预期。 一、2024 年 7 月 15 日至本公告日，公司使用部分闲置募集资金进行现金管 理到期赎回的情况 公司于 2024 年 7 月 15 日使用可转债闲置募集资金 5,000 万元人民币购买了 杭州银行股份有限公司的大额存单，具体内容详见公司于 2024 年 7 月 16 日披露 的《上海荣泰健康科技股份有限公司关于使用可转债闲置募集资金现金管理赎回 并继续进行现金管理的公告》（公告编号：2024-050）。公司已于 2025 年 7 月 1 日将上述大额存单的本金 5,000 万元及收益 153.86 万元全部收回。 二、本次现金管理的情况概述 （一）现金管理目的 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金现金管理赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 ...

证券代码：603579 证券简称：荣泰健康 公告编号：2025-044 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于公司可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）可转债发行情况 经中国证券监督管理委员会《关于核准上海荣泰健康科技股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]2139 号）核准，上海荣泰健康科 技股份有限公司（以下简称"公司"）于 2020 年 10 月 30 日公开发行了 600 万张 可转换公司债券，每张面值 100 元，发行总额 60,000.00 万元，期限 6 年，票面 利率：第一年 0.50%、第二年 0.70%、第三年 1.00%、第四年 1.50%、第五年 2.50%、 第六年 3.00%。 （二）可转债上市情况 经上海证券交易所《自律监管决定书》[2020]372 号文同意，公司 60,000.00 万元可转换公司债券于 2020 年 11 月 20 日起在上海证券交易所挂牌交易，债券 ...

Company Overview - The company is Shanghai Rongtai Health Technology Corporation Limited, primarily engaged in the design, research and development, production, and sales of massage equipment [11][12] - The company aims to provide a healthy and fashionable lifestyle to global users, focusing on shared massage services and experiences [11] Financial Performance - In the 2024 fiscal year, the company achieved a consolidated operating revenue of RMB 1,596.87 million, a decrease of 13.92% compared to the previous year [12][14] - The total profit for the year was RMB 209.99 million, down 8.77% year-on-year, while the net profit attributable to the parent company was RMB 163.21 million, a decline of 12.47% [12][14] - The company's total assets increased by 10.55% to RMB 3,742.04 million, and the net assets attributable to shareholders rose by 2.30% to RMB 2,014.12 million [14] Business Segmentation - The main business segments include manufacturing and service, with manufacturing accounting for RMB 1,569.96 million in revenue, down 14.64% year-on-year, and a gross margin of 31.44% [13] - The service segment generated RMB 4.99 million, with a gross margin of 68.47%, reflecting a decrease of 17.30% in revenue compared to the previous year [13] Product Performance - The primary products are massage chairs and small massage devices, with massage chairs generating RMB 1,031.44 million in revenue, a decrease of 14.05% year-on-year [15] - The gross margin for massage chairs was 32.06%, while small massage devices had a gross margin of 68.46%, showing an increase of 10.98 percentage points [15] Fundraising and Use of Proceeds - The company raised a total of RMB 600 million through the issuance of convertible bonds, with a net amount of RMB 593.98 million after expenses [12][14] - The funds are primarily allocated to the construction of a massage chair manufacturing base in Huzhou, Zhejiang [12][14] Debt and Credit Rating - The company’s convertible bonds have a credit rating of AA- with a stable outlook, as assessed by Shanghai New Century Credit Rating Co., Ltd [9] - The actual controller of the company, Lin Qi, has provided a guarantee for the bonds, covering 100% of the principal and interest [10]

股票代码：603579.SH 股票简称：荣泰健康 债券代码：113606.SH 债券简称：荣泰转债 上海荣泰健康科技股份有限公司 2020 年可转换公司债券 年度受托管理事务报告 （2024 年度） 债券受托管理人： （海口市南沙路 49 号通信广场二楼） 二〇二五年六月 重要声明 万和证券股份有限公司（以下简称"万和证券"）编制本报告的内容及信息来 源于上海荣泰健康科技股份有限公司（以下简称"荣泰健康"、"发行人"或"公司"） 对外公布的《上海荣泰健康科技股份有限公司 2024 年年度报告》等相关公开信 息披露文件、第三方中介机构出具的专业意见以及发行人向万和证券提供的资 料。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为万和证券所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，万和证 券不承担任何责任。 1 | | | 第一节 公司债券概要 一、发行人名称 中文名称：上海荣泰健康科技股份有限公司 英文名称：Shanghai Rongtai Health Technology Corporation Lim ...

Core Viewpoint - The brain-computer interface sector has seen a significant increase of 5.17%, ranking second among concept sectors, with 30 stocks rising, including notable gains from Xiangyu Medical and others [1][2]. Sector Performance - The brain-computer interface sector recorded a daily increase of 5.17%, with the top-performing stocks including Xiangyu Medical (20% limit up), Jihua Group, Innovation Medical, and Rongtai Health, all hitting the limit up [1][2]. - Other notable gainers in the sector included Aipeng Medical (10.82%), Mailande (8.71%), and Yingqu Technology (7.79%) [1]. Capital Flow - The brain-computer interface sector attracted a net inflow of 606 million yuan from main funds, with 19 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2]. - Innovation Medical led the sector with a net inflow of 312 million yuan, followed by Lepu Medical, Rongtai Health, and Hanwei Technology with net inflows of 99.42 million yuan, 74.91 million yuan, and 65.52 million yuan respectively [2][3]. Capital Inflow Ratios - Jihua Group and Rongtai Health had the highest net inflow ratios at 29.79% and 22.35% respectively, indicating strong investor interest [3]. - Other companies with notable inflow ratios included Junpu Intelligent (18.98%) and Innovation Medical (17.73%) [3].

Market Overview - The market experienced a rebound with the ChiNext Index leading the gains. The military industry sector saw significant growth, with over 20 stocks including Changcheng Military and Hunan Tianyan hitting the daily limit. The stablecoin concept also surged, with stocks like Hopu Co. and Xiexin Energy reaching their limits. Brain-computer interface stocks rose, with Xiangyu Medical and Innovation Medical hitting the limit. Overall, more than 4,000 stocks in Shanghai and Shenzhen markets were in the green, with a total transaction volume of 1.51 trillion [1]. Hot Topics Military Industry - The military sector continued its upward trend, with stocks like Changcheng Military, Feiyada, and Zhongguang Defense hitting consecutive limits. Hunan Tianyan and Beifang Navigation also saw significant rebounds [4]. RWA (Real World Assets) - The RWA sector experienced substantial gains, with stocks like Hopu Co. and Hangzhou Garden hitting their limits. The market is witnessing a rapid growth of RWA ecosystem participants, including issuers, custodial banks, and investors, which may present investment opportunities in asset operation, banking IT, and cross-border payments [6][8]. Brain Science - The brain science sector saw significant increases, with stocks like Rongtai Health and Innovation Medical hitting their limits. Recent developments from Neuralink, including clinical trials for brain-computer interfaces, have generated excitement in the market. The brain-computer interface market in China is projected to reach 3.2 billion by 2024 and exceed 5.5 billion by 2027, with global applications expected to reach between 40 billion to 145 billion by 2030-2040 [9][10][11].